


PHARMACEUTICAL 2021

## ABBOTT LABORATORIES Rank 42 of 402









RealRate

PHARMACEUTICAL 2021



ABBOTT LABORATORIES Rank 42 of 402

The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 210% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	20,441,000
Cost of Goods Sold	15,003,000
Intangible Assets	38,528,000
Liabilities, Current	11,907,000
Liabilities, Non-Current	0
Other Assets	4,550,000
Other Compr. Net Income	-481,000
Other Expenses	3,175,000
Other Liabilities	0
Other Net Income	181,000
Other Revenues	34,608,000
Property and Equipment	9,029,000
Research and Development	2,420,000
Selling, General and Administrative Expense	9,696,000

Output Variable	Value in 1000 USD
Assets	72,548,000
Liabilities	11,907,000
Expenses	30,294,000
Revenues	34,608,000
Stockholders Equity	60,641,000
Net Income	4,495,000
Comprehensive Net Income	4,254,500
Economic Capital Ratio	257%

